Stay updated on Weekly Insulin Icodec with Semaglutide in Type 2 Diabetes Clinical Trial
Sign up to get notified when there's something new on the Weekly Insulin Icodec with Semaglutide in Type 2 Diabetes Clinical Trial page.

Latest updates to the Weekly Insulin Icodec with Semaglutide in Type 2 Diabetes Clinical Trial page
- Check6 days agoChange DetectedA new Revision: v3.4.1 was added and Revision: v3.4.0 was removed from the record history.SummaryDifference0.1%

- Check13 days agoNo Change Detected
- Check28 days agoChange DetectedThe revision history now lists a new entry Revision: v3.3.4, replacing the previous Revision: v3.3.3 in the Study Record Versions; to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check49 days agoChange DetectedThe page footer updates to include Revision: v3.3.3 and removes HHS Vulnerability Disclosure and Revision: v3.3.2, reflecting minor administrative changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check77 days agoChange DetectedVersion history shows the addition of Revision: v3.3.2 and removal of Revision: v3.2.0, which are metadata changes to the record history. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check84 days agoChange DetectedThe government funding/operating status notice on the page was removed. This change does not modify the trial details or history.SummaryDifference0.6%

- Check107 days agoChange DetectedThe new screenshot shows a slightly different header/footer layout with no changes to the study data or statuses. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Weekly Insulin Icodec with Semaglutide in Type 2 Diabetes Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Weekly Insulin Icodec with Semaglutide in Type 2 Diabetes Clinical Trial page.